Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response

The receptor binding domain (RBD) of the SARS-CoV-2 spike protein is the primary target of neutralizing antibodies and is a component of almost all current vaccines. Here, RBD immunogens were created with stabilizing amino acid changes that improve the neutralizing antibody response, as well as char...

Descripción completa

Detalles Bibliográficos
Autores principales: Dickey, Thayne H., Tang, Wai Kwan, Butler, Brandi, Ouahes, Tarik, Orr-Gonzalez, Sachy, Salinas, Nichole D., Lambert, Lynn E., Tolia, Niraj H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9473567/
https://www.ncbi.nlm.nih.gov/pubmed/36103542
http://dx.doi.org/10.1126/sciadv.abq8276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9473567/
https://www.ncbi.nlm.nih.gov/pubmed/36103542
http://dx.doi.org/10.1126/sciadv.abq8276

Ejemplares similares